Carlos G. Romo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carlos G. Romo has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Jaishri O. Blakeley
Johns Hopkins University School of Medicine, Baltimore, MD
11 shared publications - Stuart A. Grossman
Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine , Baltimore
6 shared publications - David M. Peereboom
Cleveland Clinic, Cleveland, OH
5 shared publications - K. Ina Ly
Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
5 shared publications - Louis Burton Nabors
Division of Neuro-oncology, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL
5 shared publications - Matthew R. Steensma
Department of Cell Biology, , Grand Rapids, MI, United States
5 shared publications
Latest Publications
- Open Access
Clinical and Imaging Phenotype of Schwannomatosis in Children, Adolescents and Young Adults
Background/Objectives: To characterize the clinical and imaging phenotypes of schwannomatosis (SWN) in children, adolescents, and young adults (AYAs). Methods: This single-center retrospective cohort study included patients (age ≤ 25 years) with suspected SWN with archived magnetic resonance imaging (MRI) at Johns Hopkins between 2020–2026. Clinical characteristics, genetic testing results, and tumor imaging (including anatomic distribution), and treatment approaches were reviewed. Descriptive statistics were performed. Results: In total, thirty-eight patients with suspected SWN were identified (median age 20 years, range 6–25; 32% female). NF2-related SWN was the most common diagnosis (31/38, 82%; de novo: 24/31 (77%) and familial: 7/31 (23%)), followed by LZTR1-SWN (n = 1) and SWN-NOS/NEC (n = 2). A total of four patients (asymptomatic LZTR1 carriers (n = 2) and possible SWN (n = 2)) did not fulfill diagnostic criteria based on craniospinal and whole-body MRI. Familial NF2-SWN demonstrated a trend toward earlier presentation (median 5 vs. 8 years; p = 0.12). Visual manifestations occurred at a younger age than hearing loss (median 8 vs. 16 years; p = 0.053). Imaging burden was high (median 23 MRI/patient (range: 1–60). Bilateral vestibular schwannomas were nearly universal (30/31, 97%). Familial disease demonstrated a trend toward increased cranial meningiomas (86% vs. 54%; p = 0.20), while peripheral schwannomas (43% vs. 67%; p = 0.38) and ependymomas (14% vs. 42%; p = 0.37) were less frequent compared with de novo disease. Operative and non-operative management was documented in 65% (20/31) each. Conclusions: NF2-related SWN is the predominant subtype in a pediatric and AYA patient population and was associated with substantial early tumor burden at a tertiary specialty NF center.
Open AccessClinical and Imaging Phenotype of Schwannomatosis in Children, Adolescents and Young Adults
Background/Objectives: To characterize the clinical and imaging phenotypes of schwannomatosis (SWN) in children, adolescents, and young adults (AYAs). Methods: This single-center retrospective cohort study included patients (age ≤ 25 years) with suspected SWN with archived magnetic resonance imaging (MRI) at Johns Hopkins between 2020–2026. Clinical characteristics, genetic testing results, and tumor imaging (including anatomic distribution), and treatment approaches were reviewed. Descriptive statistics were performed. Results: In total, thirty-eight patients with suspected SWN were identified (median age 20 years, range 6–25; 32% female). NF2-related SWN was the most common diagnosis (31/38, 82%; de novo: 24/31 (77%) and familial: 7/31 (23%)), followed by LZTR1-SWN (n = 1) and SWN-NOS/NEC (n = 2). A total of four patients (asymptomatic LZTR1 carriers (n = 2) and possible SWN (n = 2)) did not fulfill diagnostic criteria based on craniospinal and whole-body MRI. Familial NF2-SWN demonstrated a trend toward earlier presentation (median 5 vs. 8 years; p = 0.12). Visual manifestations occurred at a younger age than hearing loss (median 8 vs. 16 years; p = 0.053). Imaging burden was high (median 23 MRI/patient (range: 1–60). Bilateral vestibular schwannomas were nearly universal (30/31, 97%). Familial disease demonstrated a trend toward increased cranial meningiomas (86% vs. 54%; p = 0.20), while peripheral schwannomas (43% vs. 67%; p = 0.38) and ependymomas (14% vs. 42%; p = 0.37) were less frequent compared with de novo disease. Operative and non-operative management was documented in 65% (20/31) each. Conclusions: NF2-related SWN is the predominant subtype in a pediatric and AYA patient population and was associated with substantial early tumor burden at a tertiary specialty NF center.
- Open Access
- 8 July 2026
- Published by Springer Nature in Research Square
Nutritional Considerations and Dietary Interventions for Patients with Neurofibromatosis Type 1: A Systematic Review
Background There is a paucity in the literature that comprehensively analyzes previous and current articles related to nutrient intake and the impact of diet in people with neurofibromatosis type 1 (NF1). This systematic review aims to explore the available literature to assess results of clinical studies evaluating specific diets or nutritional supplements for individuals with NF1. Methods This systematic review was written according to PRISMA guidelines. Articles that described the diets and nutraceuticals as applied to people with NF1 were identified and evaluated after searching PubMed, Embase, PLOS One, and Cochrane for all the relevant articles. Results A total of 183 studies were screened for eligibility. 13 met the inclusion criteria and were included in this review. Manuscripts included case reports, case series, retrospective, and prospective studies. Topics included vitamin D and bone metabolism, nutritional supplements, glucose metabolism, and nutritional intake. Conclusion Data regarding the effects of diet or nutritional supplements in people with NF1 is limited. Available studies suggest that a diet composed of therapeutic elements, such as medium-chain fatty acids, calcium, and vitamin D, aids in bone growth and density, and muscle lipolysis. A single clinical trial suggests that L-carnitine supplementation is feasible and might result in improved functional muscle performance in children with NF1. However, these conclusions are likely to only be applicable to a small population of people with NF1 and did not result in significant benefit. Further research is essential to better understand the role nutrition plays in the quality of life of NF1 patients.
- 8 July 2026
- Published by Springer Nature in Research Square
Open AccessNutritional Considerations and Dietary Interventions for Patients with Neurofibromatosis Type 1: A Systematic Review
Background There is a paucity in the literature that comprehensively analyzes previous and current articles related to nutrient intake and the impact of diet in people with neurofibromatosis type 1 (NF1). This systematic review aims to explore the available literature to assess results of clinical studies evaluating specific diets or nutritional supplements for individuals with NF1. Methods This systematic review was written according to PRISMA guidelines. Articles that described the diets and nutraceuticals as applied to people with NF1 were identified and evaluated after searching PubMed, Embase, PLOS One, and Cochrane for all the relevant articles. Results A total of 183 studies were screened for eligibility. 13 met the inclusion criteria and were included in this review. Manuscripts included case reports, case series, retrospective, and prospective studies. Topics included vitamin D and bone metabolism, nutritional supplements, glucose metabolism, and nutritional intake. Conclusion Data regarding the effects of diet or nutritional supplements in people with NF1 is limited. Available studies suggest that a diet composed of therapeutic elements, such as medium-chain fatty acids, calcium, and vitamin D, aids in bone growth and density, and muscle lipolysis. A single clinical trial suggests that L-carnitine supplementation is feasible and might result in improved functional muscle performance in children with NF1. However, these conclusions are likely to only be applicable to a small population of people with NF1 and did not result in significant benefit. Further research is essential to better understand the role nutrition plays in the quality of life of NF1 patients.
- Open Access
- 12 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1599-1611
Evaluating “brain permeability”: A critical issue for the development of therapeutic agents for primary and metastatic brain tumors
Current assessments of brain permeability rely predominantly on drug delivery to contrast-enhancing tumor regions. However, substantial portions of central nervous system (CNS) tumors reside within non-enhancing brain (NEB), where drug concentrations frequently remain subtherapeutic. This collaborative Adult Brain Tumor Consortium and Food and Drug Administration workshop aimed to identify criteria for defining NEB permeability to accomplish two critical objectives: 1) allocate clinical trial resources toward agents achieving therapeutic NEB concentrations and 2) minimize systemic toxicity when CNS benefit is improbable. The workshop systematically evaluated permeability assessment modalities, including drug physicochemical properties, in vitro blood-brain barrier models, and penetration into cerebrospinal fluid and normal rodent brain. Methodological approaches to determine requisite NEB drug concentrations and approaches to measuring NEB pharmacokinetics and pharmacodynamics were examined. This culminated in developing the Non-Enhancing Brain Permeability Index (NEBPI), which assigns therapeutic agents to three categories: sufficiently permeable, insufficiently permeable, or impermeable. The NEBPI provides a standardized framework to assist investigators and regulatory agencies to evaluate NEB penetration before human efficacy studies are initiated for agents that require direct tumor contact. Assessing NEB drug penetration is critical to improving outcomes in CNS tumors and reducing the incidence of brain metastases in systemic malignancies.
- 12 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1599-1611
Open AccessEvaluating “brain permeability”: A critical issue for the development of therapeutic agents for primary and metastatic brain tumors
Current assessments of brain permeability rely predominantly on drug delivery to contrast-enhancing tumor regions. However, substantial portions of central nervous system (CNS) tumors reside within non-enhancing brain (NEB), where drug concentrations frequently remain subtherapeutic. This collaborative Adult Brain Tumor Consortium and Food and Drug Administration workshop aimed to identify criteria for defining NEB permeability to accomplish two critical objectives: 1) allocate clinical trial resources toward agents achieving therapeutic NEB concentrations and 2) minimize systemic toxicity when CNS benefit is improbable. The workshop systematically evaluated permeability assessment modalities, including drug physicochemical properties, in vitro blood-brain barrier models, and penetration into cerebrospinal fluid and normal rodent brain. Methodological approaches to determine requisite NEB drug concentrations and approaches to measuring NEB pharmacokinetics and pharmacodynamics were examined. This culminated in developing the Non-Enhancing Brain Permeability Index (NEBPI), which assigns therapeutic agents to three categories: sufficiently permeable, insufficiently permeable, or impermeable. The NEBPI provides a standardized framework to assist investigators and regulatory agencies to evaluate NEB penetration before human efficacy studies are initiated for agents that require direct tumor contact. Assessing NEB drug penetration is critical to improving outcomes in CNS tumors and reducing the incidence of brain metastases in systemic malignancies.
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (1)
Variant Resolution Through RNA Testing and Affected Tissue Analysis in the Neurofibromatoses
This series reports 3 unrelated individuals with features of neurofibromatosis type 1 (NF1) and/or schwannomatosis (SWN) in whom variants of uncertain significance (VUSs) were resolved through RNA testing and tissue analysis, highlighting the clinical impact of these tests. Each patient's genetic testing identified a VUS that could have explained their clinical presentation. Because diagnostic criteria were not met, we performed VUS resolution. For patient 1, we conducted tissue analysis and RNA-based Sanger sequencing. For patients 2 and 3, RNA-based Sanger sequencing was pursued. Tissue analysis and RNA testing reclassified the NF1 c.8050 + 93A>T VUS in patient 1 as pathogenic, confirming diagnosis of NF1. RNA testing of the NF2 c.448-5T>C VUS in patient 2 reclassified the variant as likely benign, ruling out diagnosis of germline neurofibromatosis type 2 (NF2). RNA testing of the SPRED1 c.377-13T>A VUS in patient 3 reclassified the variant as likely benign, ruling out diagnosis of germline Legius syndrome. Because diagnostic criteria for NF1 and SWN include genetic testing, resolving VUSs in those who do not meet criteria is crucial for clinical care. In this article, we report 3 cases in which RNA testing and tissue analysis clarified pathogenicity of VUSs, thereby affecting clinical care, and in one case providing a definitive diagnosis.
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (1)
Open AccessVariant Resolution Through RNA Testing and Affected Tissue Analysis in the Neurofibromatoses
This series reports 3 unrelated individuals with features of neurofibromatosis type 1 (NF1) and/or schwannomatosis (SWN) in whom variants of uncertain significance (VUSs) were resolved through RNA testing and tissue analysis, highlighting the clinical impact of these tests. Each patient's genetic testing identified a VUS that could have explained their clinical presentation. Because diagnostic criteria were not met, we performed VUS resolution. For patient 1, we conducted tissue analysis and RNA-based Sanger sequencing. For patients 2 and 3, RNA-based Sanger sequencing was pursued. Tissue analysis and RNA testing reclassified the NF1 c.8050 + 93A>T VUS in patient 1 as pathogenic, confirming diagnosis of NF1. RNA testing of the NF2 c.448-5T>C VUS in patient 2 reclassified the variant as likely benign, ruling out diagnosis of germline neurofibromatosis type 2 (NF2). RNA testing of the SPRED1 c.377-13T>A VUS in patient 3 reclassified the variant as likely benign, ruling out diagnosis of germline Legius syndrome. Because diagnostic criteria for NF1 and SWN include genetic testing, resolving VUSs in those who do not meet criteria is crucial for clinical care. In this article, we report 3 cases in which RNA testing and tissue analysis clarified pathogenicity of VUSs, thereby affecting clinical care, and in one case providing a definitive diagnosis.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (1)
The interconnection of multiple sclerosis and neurofibromatosis type 1: A single institution retrospective study and systematic review
Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic neurocutaneous disorder. Multiple sclerosis (MS) is an immune-mediated demyelinating disorder of the central nervous system. The rates of occurrence are higher than expected by chance, suggesting that an underlying predisposition may exist. We aimed to systematically review the literature to better understand the concurrence and contribute four additional patients to the existing literature. Methods: This study is a systematic review as well as retrospective case series. Pubmed, Embase, Cochrane, Scopus, and Web of Science were queried for full articles in English reporting on cases of concurrent NF1 and MS between 1990 and 2023. Results: The systematic review revealed 34 reported cases of patients with both NF1 and MS across 18 papers. Ten patients had primary progressive MS, seven had relapse-remitting MS, five had secondary progressive MS, and 12 did not have a specific MS classification. Thirty-three had at least one reported brain lesion and 18 had at least one reported spine lesion. Our cohort contains four female patients; all with brain lesions and three with spinal lesions. Conclusion: Although rare, NF1 and MS can occur within the same patient. Previous literature has been inconsistent in the information reported about patients with these concurrent diagnoses. Additional research is required to better understand the concurrent disease processes, whether a predisposition exists, as well as the best therapeutic approaches for these patients.
- 1 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (1)
Open AccessThe interconnection of multiple sclerosis and neurofibromatosis type 1: A single institution retrospective study and systematic review
Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic neurocutaneous disorder. Multiple sclerosis (MS) is an immune-mediated demyelinating disorder of the central nervous system. The rates of occurrence are higher than expected by chance, suggesting that an underlying predisposition may exist. We aimed to systematically review the literature to better understand the concurrence and contribute four additional patients to the existing literature. Methods: This study is a systematic review as well as retrospective case series. Pubmed, Embase, Cochrane, Scopus, and Web of Science were queried for full articles in English reporting on cases of concurrent NF1 and MS between 1990 and 2023. Results: The systematic review revealed 34 reported cases of patients with both NF1 and MS across 18 papers. Ten patients had primary progressive MS, seven had relapse-remitting MS, five had secondary progressive MS, and 12 did not have a specific MS classification. Thirty-three had at least one reported brain lesion and 18 had at least one reported spine lesion. Our cohort contains four female patients; all with brain lesions and three with spinal lesions. Conclusion: Although rare, NF1 and MS can occur within the same patient. Previous literature has been inconsistent in the information reported about patients with these concurrent diagnoses. Additional research is required to better understand the concurrent disease processes, whether a predisposition exists, as well as the best therapeutic approaches for these patients.
- 25 October 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (3) , 560-569
Imaging features and the role of image-guided biopsy for assessment of premalignant versus malignant peripheral nerve sheath tumors in neurofibromatosis type 1
Background: To compare the magnetic resonance imaging (MRI) features of histologically proven premalignant peripheral nerve sheath tumors (PNSTs) with high-grade malignant PNST and explore the utility of core needle biopsy (CNB) for confirming the diagnosis in people with neurofibromatosis type 1 (NF1). Methods: This study analyzed MRIs obtained from people with NF1 and histologically confirmed premalignant PNST (atypical neurofibromatous neoplasm of uncertain biologic potential [ANNUBP] or low-grade MPNST) or high-grade malignant PNST (MPNST). Demographic data, qualitative and quantitative imaging features (size and minimum apparent diffusion coefficient [ADCmin]), and diagnostic method (CNB or excision) were collected. Statistical analysis included Pearson’s chi-squared, Mann-Whitney U-tests, and Benjamini-Hochberg method. Results: A total of 41 tumors in 40 patients (20 females [median age: 35, range: 14-66] with high-grade MPNST (n = 30) or premalignant PNSTs (n = 11)) were included. The presence of intralesional necrosis, perilesional edema, and perilesional enhancement (P < .05); greater T2 heterogeneity (P = .001); a higher largest and average diameter (P = .014 and P = .018, respectively); and a lower ADCmin (P < .001) were associated with high-grade MPNST. When applying a binary classification scheme of premalignant PNST versus high-grade MPNST, CNB offered the correct diagnosis in 93% (27/29) of the PNSTs. Conclusion: The presence of intralesional necrosis, perilesional enhancement, and edema; higher T2 heterogeneity; large diameter (>10.5 cm) and average diameter (8.3 cm); and a lower ADCmin (<0.7 × 10−³ mm²/s) are associated with high-grade MPNST in people with NF1. As efforts continue to more precisely define transitional tumors molecularly, histologically, and clinically versus high-grade MPNST, these data contribute to the MRI diagnostic distinctions.
- 25 October 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (3) , 560-569
Imaging features and the role of image-guided biopsy for assessment of premalignant versus malignant peripheral nerve sheath tumors in neurofibromatosis type 1
Background: To compare the magnetic resonance imaging (MRI) features of histologically proven premalignant peripheral nerve sheath tumors (PNSTs) with high-grade malignant PNST and explore the utility of core needle biopsy (CNB) for confirming the diagnosis in people with neurofibromatosis type 1 (NF1). Methods: This study analyzed MRIs obtained from people with NF1 and histologically confirmed premalignant PNST (atypical neurofibromatous neoplasm of uncertain biologic potential [ANNUBP] or low-grade MPNST) or high-grade malignant PNST (MPNST). Demographic data, qualitative and quantitative imaging features (size and minimum apparent diffusion coefficient [ADCmin]), and diagnostic method (CNB or excision) were collected. Statistical analysis included Pearson’s chi-squared, Mann-Whitney U-tests, and Benjamini-Hochberg method. Results: A total of 41 tumors in 40 patients (20 females [median age: 35, range: 14-66] with high-grade MPNST (n = 30) or premalignant PNSTs (n = 11)) were included. The presence of intralesional necrosis, perilesional edema, and perilesional enhancement (P < .05); greater T2 heterogeneity (P = .001); a higher largest and average diameter (P = .014 and P = .018, respectively); and a lower ADCmin (P < .001) were associated with high-grade MPNST. When applying a binary classification scheme of premalignant PNST versus high-grade MPNST, CNB offered the correct diagnosis in 93% (27/29) of the PNSTs. Conclusion: The presence of intralesional necrosis, perilesional enhancement, and edema; higher T2 heterogeneity; large diameter (>10.5 cm) and average diameter (8.3 cm); and a lower ADCmin (<0.7 × 10−³ mm²/s) are associated with high-grade MPNST in people with NF1. As efforts continue to more precisely define transitional tumors molecularly, histologically, and clinically versus high-grade MPNST, these data contribute to the MRI diagnostic distinctions.
- 18 July 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (6) , 1051-1057
Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas
Background: BRAF alterations are common in pediatric low-grade gliomas (LGG) and a subset of high-grade gliomas (HGG) in adults and children. BRAF-targeted therapy can be effective at preventing tumor growth, though resistance commonly emerges in HGG. Recently, tovorafenib was FDA approved for recurrent or refractory LGG with BRAFV600 alterations or BRAF rearrangements. While the trial showed it is effective for children with LGG previously treated with BRAF or MEK inhibitors, the safety in adults and efficacy in HGG is unknown. Methods: A cohort of appropriate patients was identified through routine clinical care. This research was conducted in accordance with IRB regulations with a waiver of written consent. Results: Seven adults (5 HGG, 2 LGG) who received tovorafenib were identified. All patients had received prior BRAF-targeted therapy, and all patients with HGG had received prior radiation and temozolomide as well. Three individuals (2 HGG, 1 LGG) experienced stable disease or better for 4 or more months. Median duration of treatment was 8 weeks (range 3 weeks to 10 months). Two individuals experienced CTCAE grade 4 intratumoral hemorrhage (1 HGG, 1 LGG). Two patients remain on therapy at 4 and 10 months of treatment (1 HGG, 1 LGG). Conclusion: Our experience with tovorafenib indicates some limited efficacy in HGG in combination with other standard treatments. These observations demonstrate the need for further clinical trials in patients with HGG to understand potential clinical utility, either earlier in the disease course or in combination with other therapies.
- 18 July 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (6) , 1051-1057
Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas
Background: BRAF alterations are common in pediatric low-grade gliomas (LGG) and a subset of high-grade gliomas (HGG) in adults and children. BRAF-targeted therapy can be effective at preventing tumor growth, though resistance commonly emerges in HGG. Recently, tovorafenib was FDA approved for recurrent or refractory LGG with BRAFV600 alterations or BRAF rearrangements. While the trial showed it is effective for children with LGG previously treated with BRAF or MEK inhibitors, the safety in adults and efficacy in HGG is unknown. Methods: A cohort of appropriate patients was identified through routine clinical care. This research was conducted in accordance with IRB regulations with a waiver of written consent. Results: Seven adults (5 HGG, 2 LGG) who received tovorafenib were identified. All patients had received prior BRAF-targeted therapy, and all patients with HGG had received prior radiation and temozolomide as well. Three individuals (2 HGG, 1 LGG) experienced stable disease or better for 4 or more months. Median duration of treatment was 8 weeks (range 3 weeks to 10 months). Two individuals experienced CTCAE grade 4 intratumoral hemorrhage (1 HGG, 1 LGG). Two patients remain on therapy at 4 and 10 months of treatment (1 HGG, 1 LGG). Conclusion: Our experience with tovorafenib indicates some limited efficacy in HGG in combination with other standard treatments. These observations demonstrate the need for further clinical trials in patients with HGG to understand potential clinical utility, either earlier in the disease course or in combination with other therapies.
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in Neurology Education
- Vol. 4 (2) , e200218
Curriculum Innovation: The Osler Apprenticeship in Neurology
Few formal programs provide structured training in medical education (MedEd) early in a learner's career. MedEd training curricula for medical students may cultivate student understanding (and thus interest) in a MedEd career. The Johns Hopkins Osler Apprenticeship (OA) in Neurology is a structured 1-year program for senior medical students (Osler Apprentices/OAs) created to develop talent in MedEd. By the end of the program, OAs will be better able to (1) cultivate and sustain longitudinal mentorship relationships; (2) design, implement, and present a MedEd project; (3) understand individual leadership strengths; (4) develop and refine skills in educational leadership and integrate feedback to enhance learning experiences; and (5) develop an understanding of the responsibilities of an academic educator. The OA is a 1-year program that provides learners with comprehensive exposure to MedEd through key program components of mentorship, a scholarly project, strength coaching, and leadership and experiential opportunities. To evaluate the program's impact on OAs and preceptor motivations for engagement and its benefits, we administered 3 distinct surveys to OAs at exit, OA alumni, and faculty preceptors. We implemented the 4 levels of the New World Kirkpatrick Model to evaluate the impact of the program. Twenty-four of 33 OAs (73%), 18 of 29 alumni (62%), and 6 of 7 preceptors (86%) responded to the surveys. Twenty-one OAs (88%) and 18 alumni (100%) recommended the OA to medical students (level 1). Alumni felt confident participating in educational activities (n = 15/83%), research (n = 15/83%), and leadership (n = 12/67%). Thirty-one OAs (94%) produced educational scholarship (level 2). OAs (n = 22/92%) and alumni (n = 14/78%) agreed that the OA influenced their academic practices and behaviors, and 7 alumni (39%) were recognized or awarded (level 3). Ten alumni (56%) have an educational role (level 4). Preceptors had scholarly output from the OA and reported career or personal development as key factors for participation. The OA made effective progress toward building a pathway for medical educators while supporting the careers of faculty, allowing for program sustainability. These findings suggest the OA may serve as a prototype for more formalized training programs in neurology MedEd.
- 1 June 2025
- Published by Wolters Kluwer Health in Neurology Education
- Vol. 4 (2) , e200218
Open AccessCurriculum Innovation: The Osler Apprenticeship in Neurology
Few formal programs provide structured training in medical education (MedEd) early in a learner's career. MedEd training curricula for medical students may cultivate student understanding (and thus interest) in a MedEd career. The Johns Hopkins Osler Apprenticeship (OA) in Neurology is a structured 1-year program for senior medical students (Osler Apprentices/OAs) created to develop talent in MedEd. By the end of the program, OAs will be better able to (1) cultivate and sustain longitudinal mentorship relationships; (2) design, implement, and present a MedEd project; (3) understand individual leadership strengths; (4) develop and refine skills in educational leadership and integrate feedback to enhance learning experiences; and (5) develop an understanding of the responsibilities of an academic educator. The OA is a 1-year program that provides learners with comprehensive exposure to MedEd through key program components of mentorship, a scholarly project, strength coaching, and leadership and experiential opportunities. To evaluate the program's impact on OAs and preceptor motivations for engagement and its benefits, we administered 3 distinct surveys to OAs at exit, OA alumni, and faculty preceptors. We implemented the 4 levels of the New World Kirkpatrick Model to evaluate the impact of the program. Twenty-four of 33 OAs (73%), 18 of 29 alumni (62%), and 6 of 7 preceptors (86%) responded to the surveys. Twenty-one OAs (88%) and 18 alumni (100%) recommended the OA to medical students (level 1). Alumni felt confident participating in educational activities (n = 15/83%), research (n = 15/83%), and leadership (n = 12/67%). Thirty-one OAs (94%) produced educational scholarship (level 2). OAs (n = 22/92%) and alumni (n = 14/78%) agreed that the OA influenced their academic practices and behaviors, and 7 alumni (39%) were recognized or awarded (level 3). Ten alumni (56%) have an educational role (level 4). Preceptors had scholarly output from the OA and reported career or personal development as key factors for participation. The OA made effective progress toward building a pathway for medical educators while supporting the careers of faculty, allowing for program sustainability. These findings suggest the OA may serve as a prototype for more formalized training programs in neurology MedEd.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Figure 1. Differential expression analysis based on per-pixel adavosertib mass spectrometry imaging drug distribution (p-value = 0.115, t-test). Boxplot show the median, 25% and 75% quantiles.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Figure 1. Differential expression analysis based on per-pixel adavosertib mass spectrometry imaging drug distribution (p-value = 0.115, t-test). Boxplot show the median, 25% and 75% quantiles.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Table 1. Representativeness of Study Participants.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Supplementary Table 1. Representativeness of Study Participants.